A-Alpha Bio
Latest round
- Series A
Last raised
- Jul 2023
Total raised
- $45M
Investors
- 9
About A-Alpha Bio
Founded in 2017 and based in Washington, US, A-Alpha Bio, Inc. operates as a protein-protein interaction company. The company was founded by its CEO, David Younger, and CTO, Randolph Lopez. In June 2024, A-Alpha Bio, Inc. A-Alpha Bio offers a drug discovery platform focused on understanding and manipulating protein interactions. The firm employs synthetic biology and machine learning to measure and predict these interactions. Their platform, AlphaSeq, generates extensive protein interaction data, while AlphaBind uses this data to create predictive models.
Who invested in A-Alpha Bio
9 investors across 3 rounds
See all investors in A-Alpha Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about A-Alpha Bio
Who invested in A-Alpha Bio?
A-Alpha Bio has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has A-Alpha Bio raised?
A-Alpha Bio has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did A-Alpha Bio last raise money?
A-Alpha Bio's most recent round on record is a Series A, in Jul 2023.
What does A-Alpha Bio do?
Founded in 2017 and based in Washington, US, A-Alpha Bio, Inc.
Where is A-Alpha Bio headquartered?
A-Alpha Bio is headquartered in Seattle, US.
Which VCs invest in companies like A-Alpha Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at A-Alpha Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like A-Alpha Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.